Dr. Upadhyaya on the Importance of Long-Term Follow-Up in Pediatric Patients With Ependymoma

Video

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses the importance of long-term follow-up in pediatric patients with ependymoma.

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses the importance of long-term follow-up in pediatric patients with ependymoma.

In the 10-year-long SJYC07 trial, researchers examined the use of radiation therapy for young children under the age of 3 with ependymoma. The trial reported that the use of chemotherapy and subsequent radiation is safe in treating residual cancer after surgical resection. However, Upadhyaya notes that the long-term side effects of radiation and chemotherapy are still a matter of concern. Specifically, neurocognitive deficits, endocrine issues, vascular problems, and potential secondary malignancies.

Therefore, patients who receive this protocol need to be closely monitored. At St. Jude’s, these children are monitored every 3 months with scans and physical exams. Visits are then extended to every 4 or 6 months based on the physician’s discretion and absence of recurrence. Long-term follow-up is especially important for patients with ependymoma, as those tumors can recur after the traditional 5 years of follow up.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD